

PRESS RELEASE: June 2, 2017

Travelan Increases Industry Presence with Sponsorship of ISTM and Sales Growth

- *Immuron Sponsored 15th Biennial Conference of the International Society of Travel Medicine (ISTM)*
- *Immuron hosted a panel of Gastrointestinal experts*
- *Travel medicine doctors and nurses represent a key growth driver for Travelan in the US and globally*
- *Travelan Australian Sales up 13% for FY2017 to date*
- *Travelan continues to experience strong growth in the US driven by the travel clinics channel*

Travelan Increases Industry Presence with Sponsorship of ISTM and Sales Growth

Melbourne, Australia – June 2, 2017 - Australian biopharmaceutical Company Immuron Limited (ASX:IMC) is pleased to announce that it sponsored the 15th Biennial Conference of the International Society of Travel Medicine (CISTM15) in Barcelona, Spain from the 14th - 18th of May 2017.

ISTM was attended by more than 1,500 medical health professionals from across 60 countries. As part of the conference, Immuron sponsored a satellite symposium on the “non-antibiotic options for the management of Travellers’ Diarrhoea (TD)”. The Company hosted an expert panel consisting of three Gastrointestinal (GI) health specialists who shared insight on the risks of using antibiotics for the management of travellers’ diarrhoea symptoms and non-antibiotic solutions available for this ailment. The video of the panel will be available on Immuron’s website over the next few weeks.

Sitting on the panel were three key opinion leaders in the field of gastrointestinal health:

- Dr. Herbert Dupont, M.D MACP
(Professor & Director of Centre for Infectious Diseases, University of Texas School of Public Health, Texas, US) and
- Dr. Bradley A. Connor, M.D., AGA-F, FIDSA, FACP, FRCPS (Glas).
(Clinical Professor of Medicine at Weill Cornell Medical College & Medical Director at New York Centre for Travel)
- Dr. Anu Kantele, M.D, PhD
(Professor of Infectious Diseases and Senior Medical Officer at Helsinki University Central Hospital, Finland)

Immuron US Sales Director, Travis Robins, said:

“CISTM has traditionally been a conference where travel medicine doctors and professionals converge to share the latest advancements in medicinal progress. We had an opportunity to connect with many of these key leaders who share the same concern over the increasing risks of antibiotic use in the fight against TD.”

Immuron Global Marketing Manager, David Montgomery, said:

“We were excited to host a panel of experts, all of whom are leaders in the field of GI and who share a common concern regarding the overuse of antibiotics to treat TD. We were pleased to share the insights of these experts with the CISTM15 symposium’s global audience and to highlight the benefits of Immuron’s non-antibiotic alternative for the management of travellers’ diarrhoea - Travelan.”

Travelan has been experiencing strong sales growth in both the Australian and the US travellers’ diarrhoea market and is aiming to surpass its FY2016 revenue figures in FY2017.

For the FY2017 YTD period (July 2016 – April 2017), Travelan has experienced a 13% increase in sales revenue in Australia compared to the same period last year. Immuron believes that this is the direct result of the implementation of a new Trade Marketing Strategy for Travelan in the Australian market which was premised at the Company's 2016 Annual General Meeting.

The new strategy has delivered sales results through:

- Rollout of Travelan Pharmacy staff education program to over 3000 pharmacies;
- increased point-of-sale advertising collateral;
- closer relationships with distributors and brokers; and
- improved pharmacy shelf position.

In April 2017, Travelan experienced its highest ever monthly sales in the US, which also came off the back of steady month-on-month sales revenue increases for FY2017 in comparison to FY2016. This increase in sales revenue has occurred predominantly in the Travel Clinic market through Immuron's excellent and growing partnership with Passport Health.

- - END - -

COMPANY CONTACT:

Thomas Liquard

Chief Executive Officer

Ph: +61 (0)3 9824 5254

thomasliquard@immuron.com

IMMURON INVESTOR RELATIONS:

Peter Taylor

NWR Communications

Ph: +61 (0)4 1203 6231

peter@nwrcommunications.com.au

ABOUT IMMURON:

Immuron Ltd (ASX: IMC) is a biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers' diarrhea whilst its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market. For more information visit: <http://www.immuron.com>

FORWARD-LOOKING STATEMENTS:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.